Patients with CS possess a spectrum of core and secondary clinical symptoms [1, 3, 8, 9], the variability of which may depend on the severity of the mutation in NHE6, functional overlap with other pH-regulating solute carrier proteins, or genetic-modifier effects. Here, SLC9A6 is linked to Cowden syndrome 1.